Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 5/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102536 | 1.00 | SSTR4 (0.35) | SSTR4SLC6A2SLC6A3SLC6A4ADRB2 | |
| SCHEMBL2767957 | 1.00 | SSTR4 (0.35) | SSTR4SLC6A2SLC6A3SLC6A4ADRB2 | |
| SCHEMBL17200854 | 0.87 | SSTR4 (0.35) | SSTR4SLC6A2SLC6A3SLC6A4ADRB2 | |
| SCHEMBL17448116 | 0.80 | SLC6A2 (0.35) | SSTR4SLC6A2SLC6A3SLC6A4ADRB2 | |
| SCHEMBL17448117 | 0.80 | SLC6A2 (0.35) | SSTR4SLC6A2SLC6A3SLC6A4ADRB2 | |
| SCHEMBL4302670 | 0.78 | LMNA (0.34) | BRD4 | |
| SCHEMBL5725934 | 0.77 | ALDH1A1 (0.33) | — | |
| SCHEMBL17094524 | 0.77 | ALDH1A1 (0.33) | — | |
| SCHEMBL15193782 | 0.77 | ALDH1A1 (0.33) | — | |
| SCHEMBL21111181 | 0.74 | SLC6A2 (0.34) | SSTR4SLC6A2SLC6A3SLC6A4ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180251426-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-09-06 | — | — | US | disclosed |
| US-20160304451-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-10-20 | — | — | US | disclosed |
| US-20140275063-A1 | NEW ENZYME INHIBITOR COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-7932271-B2 | Heterocyclic methyl sulfone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070254872-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20060241302-A1 | Morpholine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251426-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SSTR4 4730/4885SLC6A2 4844/4885SLC6A3 4856/4885 |
| US-20060241302-A1 | Morpholine derivatives | APP, BACE1, SMS | SSTR4 700/4885SLC6A2 1257/4885SLC6A3 2151/4885 |
| US-20160304451-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SSTR4 4730/4885SLC6A2 4844/4885SLC6A3 4856/4885 |
| US-20070254872-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | SSTR4 4531/4885SLC6A2 2010/4885SLC6A3 3139/4885 |
| US-20140275063-A1 | NEW ENZYME INHIBITOR COMPOUNDS | XDH, MAOB, MAOA | SSTR4 2512/4885SLC6A2 868/4885SLC6A3 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.